Quantificare v. Canfield Scientific: Federal Circuit Affirms Patent Unpatentable
French imaging firm Quantificare SA challenged Canfield Scientific over US10681334B2, a patent covering 3D face and body reconstruction technology. After 676 days of appellate proceedings, the Federal Circuit affirmed the underlying unpatentability finding — extinguishing Quantificare’s patent rights in this technology.
Federal Circuit kills Quantificare’s 3D imaging patent after full appeal
Quantificare SA, a French medical imaging company, appealed a ruling declaring US10681334B2 unpatentable. The patent — filed under application number US16/190401 — covers a device and method to reconstruct the face and body in three dimensions, a technology with direct commercial relevance in dermatology, aesthetics, and clinical photography. The appeal was docketed at the Federal Circuit on 19 May 2023, with Canfield Scientific, Inc. — a leading provider of medical imaging and skin analysis systems — as the respondent.
On 25 March 2025, the Federal Circuit issued its order affirming the unpatentability determination. The single-word verdict — ‘AFFIRMED’ — confirms that the appellate panel found no reversible legal or factual error in the tribunal below. For Quantificare, this means US10681334B2 is cancelled and unenforceable. For Canfield Scientific, the ruling validates its challenge strategy and removes a patent that could have obstructed its own 3D imaging product lines.
A 676-day appellate timeline is broadly consistent with Federal Circuit norms for patentability appeals, suggesting no unusual procedural complexity. The terse ‘AFFIRMED’ disposition — without a published opinion or remand — typically signals the panel found the lower tribunal’s reasoning legally sound and factually supported. What remains unknown from the public record is whether a written opinion accompanied the order, whether Quantificare pursued en banc rehearing, or whether any licensing discussions occurred in parallel.
Filing to Unpatentable in 676 days
676 days from filing to Federal Circuit decision — consistent with typical PTAB-appeal timelines
Federal Circuit affirms: what the unpatentability ruling means for both parties
Affirmance means the Federal Circuit found no reversible error
When the Federal Circuit affirms, it is confirming that the tribunal below — most likely the Patent Trial and Appeal Board — applied the correct legal standards and that its factual findings were supported by substantial evidence. The appellate court does not rehear the case de novo; it reviews for reversible error. An affirmance here means Quantificare could not demonstrate that the unpatentability finding was legally flawed or factually unsupported.
No reversible error foundUS10681334B2 is cancelled — Quantificare loses its 3D imaging IP asset
With the Federal Circuit’s affirmance, US10681334B2 is definitively unpatentable. Quantificare cannot enforce the patent, cannot license its claims, and has exhausted its appellate options at this level. The only remaining avenue would be a petition for certiorari to the Supreme Court — a rarely granted and high-bar remedy. This outcome effectively removes the patent from Quantificare’s IP portfolio and forecloses infringement actions based on these claims.
Patent cancelled and unenforceableCanfield Scientific succeeds — 3D reconstruction space cleared of this patent
Canfield Scientific’s challenge strategy, pursued through what appears to be a PTAB inter partes review or similar validity proceeding, has been fully validated. With the patent affirmed as unpatentable, Canfield faces no residual infringement risk from US10681334B2. The decision also raises the bar for any Quantificare successor patents claiming substantially similar subject matter, as the prior art and obviousness arguments accepted below now form part of the public record.
Challenge fully validated3D facial imaging sector loses a key patent barrier — FTO landscape shifts
The cancellation of US10681334B2 has sector-wide implications. Competitors developing 3D face and body reconstruction devices — whether for dermatology, aesthetics, or clinical documentation — can now operate without licensing this patent. However, the affirmance also signals that the Federal Circuit regards the prior art in this space as robust, suggesting future patents in the same technical domain will face heightened scrutiny. Companies should reassess their FTO analyses and patent filing strategies accordingly.
Freedom-to-operate improvedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Quantificare, SA | Company | Medical imaging company — holder of US10681334B2 covering 3D face/body reconstructionSearch in Eureka ↗ |
| Defendant | Canfield Scientific, Inc. | Company | Canfield Scientific, Inc. — medical imaging and skin analysis systems providerSearch in Eureka ↗ |
| Plaintiff counsel | Kevin Reiner | Attorney | Counsel for Quantificare, SASearch in Eureka ↗ |
| Plaintiff counsel | Mark D. Giarratana | Attorney | Counsel for Quantificare, SASearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Quantificare, SASearch in Eureka ↗ |
| Defendant counsel | Chelsea Murray | Attorney | Counsel for Canfield Scientific, Inc.Search in Eureka ↗ |
| Defendant counsel | Isha S. Shah | Attorney | Counsel for Canfield Scientific, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael R. Weiner | Attorney | Counsel for Canfield Scientific, Inc.Search in Eureka ↗ |
| Defendant counsel | Thomas Lee Duston | Attorney | Counsel for Canfield Scientific, Inc.Search in Eureka ↗ |
| Defendant law firm | Marshall Gerstein & Borun LLP | Law Firm | Representing Canfield Scientific, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘AFFIRMED’ — is terse but legally dispositive. At the appellate level, affirmance of an unpatentability finding means the panel applied the substantial evidence standard to PTAB fact-finding and de novo review to legal conclusions such as claim construction or obviousness as a matter of law, and found no basis to disturb the result. The absence of a remand instruction indicates the lower tribunal’s analysis was considered complete and legally sufficient. For Quantificare, no further correction is available at this level; for Canfield, the patent is permanently cancelled.
US10681334B2 — Device and Method to Reconstruct Face and Body in 3D
US10681334B2, filed under application number US16/190401, covers a device and method for reconstructing the human face and body in three dimensions. This patent sits at the intersection of computational imaging, photogrammetry, and medical aesthetics — technologies increasingly central to dermatology clinics, cosmetic surgery planning, and clinical photography platforms. The granted patent represented Quantificare’s attempt to protect a core algorithmic and hardware methodology for generating precise 3D models from 2D image captures.
In the medical imaging sector, 3D reconstruction patents carry significant commercial leverage: they underpin diagnostic tools, treatment planning software, and before-and-after documentation systems used globally. Canfield Scientific — whose VISIA and Mirror systems are widely deployed — had strong commercial incentive to challenge this patent. The Federal Circuit’s affirmance of unpatentability suggests the claimed invention did not sufficiently distinguish itself from the prior art, a finding that may cast scrutiny on related patents in Quantificare’s portfolio and on similar applications from other filers in this space.
Should you run an FTO against US10681334B2?
While US10681334B2 has been affirmed as unpatentable and is no longer enforceable, R&D and product teams developing 3D face and body reconstruction systems should not treat this cancellation as a blanket clearance. Quantificare may hold continuation or divisional patents with overlapping claims, and other market participants hold active patents in adjacent 3D imaging and photogrammetry spaces. A targeted FTO analysis remains essential before product launch or market entry.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape around 3D facial reconstruction technology — identifying live patents, continuation applications, and pending claims that could create infringement exposure even after US10681334B2’s cancellation. Eureka cross-references prosecution history, PTAB records, and forward citations to surface risks that manual searches miss, giving your legal and engineering teams a defensible clearance baseline.
Run a freedom-to-operate analysis on US10681334B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in 3D imaging and medical photography patents
Explore Federal Circuit cases involving 3D imaging, photogrammetry, and medical photography patents — including comparable PTAB affirmance outcomes in the aesthetics technology sector.
What this case signals for the 3D medical imaging IP landscape
The Federal Circuit’s affirmance reshapes the competitive patent environment for 3D face and body reconstruction technology.
Patent cancellation opens the 3D reconstruction field to competitors
With US10681334B2 affirmed as unpatentable, any company previously concerned about infringement exposure in 3D face and body reconstruction can now operate more freely. The public record of prior art arguments accepted by the PTAB and affirmed on appeal provides a useful roadmap for similar FTO and validity analyses in adjacent imaging patents.
Canfield’s success illustrates the efficacy of PTAB-route patent challenges
This outcome is consistent with broader trends showing that well-resourced defendants using inter partes review — represented here by a four-attorney team at Marshall Gerstein & Borun — can efficiently eliminate competitor patents through the PTAB rather than district court litigation. Companies facing blocking patents in the imaging sector should evaluate IPR as a primary strategic tool.
Quantificare v Canfield — key questions answered
The Federal Circuit affirmed the unpatentability of US10681334B2, a patent covering a device and method to reconstruct the face and body in 3D. The order, issued 25 March 2025, found no reversible error in the lower tribunal’s determination, effectively cancelling Quantificare’s patent.
US10681334B2 is a US patent filed under application number US16/190401, owned by Quantificare SA. It covers a device and method for three-dimensional reconstruction of the human face and body — technology used in dermatology, cosmetic surgery planning, and clinical imaging systems. The patent has been affirmed as unpatentable by the Federal Circuit.
Affirmance means the Federal Circuit reviewed the PTAB’s decision for reversible error — applying substantial evidence review to factual findings and de novo review to legal questions — and found none. The unpatentability determination stands, the patent is cancelled, and the patent holder has no further appellate remedy at this level short of a Supreme Court certiorari petition.
The cancellation means companies developing 3D face and body reconstruction products are no longer exposed to infringement claims under US10681334B2. However, FTO clearance is not absolute: Quantificare may hold related continuation patents, and other parties hold active patents in adjacent technical areas. A targeted FTO analysis covering the full 3D reconstruction patent landscape is still advisable.
The public record does not specify whether this challenge arose from a standalone IPR petition or a counterclaim to infringement proceedings. However, the patentability-focused verdict cause and the PTAB-style ‘unpatentable’ basis of termination suggest Canfield pursued an inter partes review. This strategy — invalidating a blocking patent before or during litigation — is increasingly common among well-resourced defendants in the medical imaging sector.
PatSnap Eureka searches patents and litigation data to answer instantly.